70 related articles for article (PubMed ID: 29966465)
1. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.
Manna M; Lee-Ying R; Davies G; Stewart C; Oh DH; Peters A; Stewart DA
Leuk Lymphoma; 2019 Jan; 60(1):133-141. PubMed ID: 29966465
[TBL] [Abstract][Full Text] [Related]
2. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
[TBL] [Abstract][Full Text] [Related]
3. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI; Choe H; Cohen J; Copelan E; Farooq U; Fenske TS; Freytes C; Gaballa S; Ganguly S; Jethava Y; Kamble RT; Kenkre VP; Lazarus H; Lazaryan A; Olsson RF; Rezvani AR; Rizzieri D; Seo S; Shah GL; Shah N; Solh M; Sureda A; William B; Cumpston A; Zelenetz AD; Link BK; Hamadani M
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1163-1171. PubMed ID: 29242111
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
Hamadani M; Horowitz MM
J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542
[TBL] [Abstract][Full Text] [Related]
5. Transformed lymphoma: what should I do now?
Smith S
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):306-311. PubMed ID: 33275671
[TBL] [Abstract][Full Text] [Related]
6. Follicular lymphoma.
Carbone A; Roulland S; Gloghini A; Younes A; von Keudell G; López-Guillermo A; Fitzgibbon J
Nat Rev Dis Primers; 2019 Dec; 5(1):83. PubMed ID: 31831752
[TBL] [Abstract][Full Text] [Related]
7. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
Arushi Khurana ; Mwangi R; Ansell SM; Habermann TM; Cerhan JR; Strouse C; Link BK; Wang Y; King RL; Macon WR; Villasboas JC; Witzig TE; Maurer MJ; Nowakowski GS
Blood Cancer J; 2021 Jul; 11(7):133. PubMed ID: 34274939
[TBL] [Abstract][Full Text] [Related]
8. Predicting early relapse in follicular lymphoma: have we turned a corner?
Araf S; Okosun J; Fitzgibbon J
Lancet Oncol; 2018 Apr; 19(4):441-442. PubMed ID: 29475722
[No Abstract] [Full Text] [Related]
9. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
MacManus M; Fisher R; Roos D; O'Brien P; Macann A; Davis S; Tsang R; Christie D; McClure B; Joseph D; Jayamohan J; Seymour JF
J Clin Oncol; 2018 Oct; 36(29):2918-2925. PubMed ID: 29975623
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K; Tobinai K; Kinoshita T; Ishikawa T; Hatake K; Ichikawa S; Ohmine K; Kamitsuji Y; Choi I; Chou T; Tsukasaki K; Kumagai K; Taniwaki M; Uchida T; Kikukawa Y; Kubo K; Mihara K; Tsukamoto N; Izutsu K; Yoshida I; Ishida F; Usui N; Iida S; Murayama T; Ueda E; Kuriki H; Ando K
Int J Hematol; 2018 Nov; 108(5):499-509. PubMed ID: 30027429
[TBL] [Abstract][Full Text] [Related]
11. A renaissance for autologous transplantation in follicular lymphoma?
Chaekal OK; van Besien K
Leuk Lymphoma; 2019 Jan; 60(1):3-5. PubMed ID: 29966478
[No Abstract] [Full Text] [Related]
12. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
13. Current and future therapeutic approaches for the treatment of follicular lymphoma.
Pulsoni A; Cappelli LV; Ballotta L; Canichella M; Serrao A; Annechini G; D'Elia GM; Foà R
Expert Rev Anticancer Ther; 2018 Sep; 18(9):931-941. PubMed ID: 29972084
[TBL] [Abstract][Full Text] [Related]
14. Positive Results for Tazemetostat in Follicular Lymphoma.
Cancer Discov; 2018 Aug; 8(8):OF3. PubMed ID: 29980507
[TBL] [Abstract][Full Text] [Related]
15. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
Madsen C; Clausen MR; Plesner TL; Pasanen A; Kuismanen T; Bentzen HH; Jørgensen JM; Sillesen IB; Himmelstrup BM; Rønnov-Jessen D; Jensen KR; Pettinger AM; Ludvigsen M; Leppä S; d'Amore FA
Blood Adv; 2018 Jul; 2(13):1562-1571. PubMed ID: 29976619
[TBL] [Abstract][Full Text] [Related]
16. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
18. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
19. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R
Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment in hodgkin lymphoma survivors.
Trachtenberg E; Mashiach T; Ben Hayun R; Tadmor T; Fisher T; Aharon-Peretz J; Dann EJ
Br J Haematol; 2018 Sep; 182(5):670-678. PubMed ID: 29974933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]